DKSH and pharma& Enter Exclusive Partnership to Build Asian Footprint for Pegasys®
The new collaboration will introduce the specialty care product of pharma& (zr pharma& GmbH) into Hong Kong and Macau markets, while expanding DKSH Business Unit Healthcare's portfolio of high-quality brands.
Hong Kong, July 20, 2022 - DKSH Business Unit Healthcare, a leading partner for healthcare companies seeking to grow their business in Asia and beyond, and pharma& (zr pharma& GmbH), an Austrian pharmaceutical multinational, have jointly announced their exclusive partnership.
DKSH will provide distribution, marketing and sales services as well as regulatory services to pharma& for their newly acquired specialty care product in Hong Kong, called Pegasys®. Special emphasis will be placed on expanding its channel network. The agreement covers both Hong Kong and Macau.
Pegasys® (Peginterferon alfa 2a) is used to treat patients suffering from Chronic Hepatitis B (CHB) and Chronic Hepatitis C (CHC). The medicine can be administered as a monotherapy or in combination with other medicinal products.
Mr. Kaustav Chatterjee, Commercial Operations Director, pharma&, said: "pharma& is committed to the well-being of our niche patient populations globally and to ensuring that Pegasys® continues to be
provided to those in need. We are excited to partner with DKSH Hong Kong for Pegasys®, as we believe that they have the knowledge and the experience to serve these patient populations and the healthcare professionals who have known and trusted Pegasys® for many years."
Wai Ting Fong, Head of Management and Vice President, Healthcare, DKSH Hong Kong, equally welcomed the partnership: "We are delighted to partner with pharma& to bring niche and original productsto patients in Hong Kong and Macau. With our in-depthexperience and our broad network of healthcare professionals in these two markets, we are confident to effectively support pharma&'s expansion withinand beyond Asia."
About zr pharma& GmbH
pharma& is a privately owned company, aiming at satisfying needs for niche, original, Specialty Care products. Its commitment to patient access for well-established original Specialty Care medicines and its worldwide presence of own subsidiaries, affiliated companies and partnerships, secure sustainable product availability in markets around the world. www.pharmaand.com
DKSH's purpose is to enrich people's lives. For more than 150 years, we have been delivering growth for companies in Asia and beyond across our Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, we offer sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales services. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 36 markets with 33,100 specialists, generating net sales of CHF 11.1 billion in 2021. The DKSH Business Unit Healthcare distributes pharmaceuticals, consumer health and over-the-counter (OTC) products as well as medical
devices. With around 7,290 specialists, the Business Unit generated net sales of CHF 5.6 billion in 2021. www.dksh.com/hec